Dare Bioscience Investor Presentation Deck
XACIATO - Commercial License Agreement with Organon¹
March 2022 - Organon and Daré
announced they entered into an
agreement whereby Organon will license
global rights to XACIATO. The license
became effective June 2022.
Organon is a global healthcare company
formed through a spin-off from Merck & Co.,
Inc., Rahway, NJ, USA, (NYSE: MRK) known
as MSD outside of the United
States and Canada, to focus on improving
the health of women throughout their lives.
The license became effective June 2022.
• Daré received a $10 million upfront payment from Organon
in 3Q 2022.
•Daré is eligible to receive potential milestone payments of up
to $182.5 million and tiered double-digit royalties based on net
sales.
We believe Organon shares our commitment to advance critically needed innovations in women's health. We are excited to be
collaborating with one of the premier companies in women's health as we believe that Organon's commercial capabilities will
ensure that XACIATO reaches the women most impacted by bacterial vaginosis.
1. https://ir.darebioscience.com/news-releases/news-release-details/organon-enters-global-license-agreement-commercialize-dare
19View entire presentation